Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

y participants were encouraging. Genzyme expects to release

results by mid year for a larger number of patients, including results

for those patients who have completed the one year trial. Final

results for all trial participants will be available in the first

quarter of 2009. Genzyme is currently developing clinical trial

protocols for two Phase 3 studies of Genz-112638, and the company

anticipates initiating these studies early next year. Genzyme believes

that this oral product may offer a more convenient treatment option for

some patients.

Mipomersen for high-risk cardiovascular disease

Genzyme expects to finalize its license of mipomersen from Isis

Pharmaceuticals in the second quarter and subsequently communicate a

development plan for the product. Mipomersen is a lipid-lowering agent

being developed primarily for patients at significant cardiovascular

risk who are unable to achieve target cholesterol levels with statins

alone or who are intolerant of statins. The product offers an

innovative approach to addressing a serious unmet medical need, and

Genzyme believes it could prove to be the most effective lipid-lowering

agent for high risk cardiovascular disease patients for whom

conventional therapies are not sufficient. The product may provide

significant benefit over the standard of care and targets a well-defined

and severely ill patient population. Mipomersen is currently being

studied in a Phase 3 clinical trial involving patients with homozygous

familial hypercholesterolemia.

This press release contains forward-looking statements regarding Genzyme's financial outlook and business plans and strategies, including without limitation: its Q2 2008, YE 2008 and YE 20011 earnings guidance; its anticipated CAGR through 2011; its expectations for approval of Myo
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood Registry® ... of the 10th Annual World Stem Cell Summit, the largest ... The 2014 World Stem Cell Summit will be held December ... Texas . The World Stem ... of lifesaving cures and therapies, convening the most prominent figures ...
(Date:11/18/2014)... 2014 Athena Signature Series: Turning Cancer ‘Off’ ... Emerson, a professor in the Regulatory Biology Laboratory at the ... discovery points to an “off switch” for drug resistance in ... her local research is making a global impact in the ... then join host Cheryl K. Goodman, CEO of Social Global ...
(Date:11/18/2014)... 18, 2014 2014 Deep ... is professional and in-depth report on Polytetrahydrofuran ... information, including its definition, characterization, application, and ... This exploration covers the worldwide business investigation, ... examination covering macroeconomic environment & financial circumstance ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... Empowers Users to Take Full Control of the ... to Results Disclosure - while Adhering to Changing ... to Manage Their Clinical Trial Registration and Results ... ( http://www.intrasphere.com ), a ...
... , - European Operating ... Healthcare Educational Program, Accepted,for Accreditation , ... healthcare barrier,protective solutions, has announced it has taken a ... the area of continued,education. , ...
... developed an entirely new method for starting chemical reactions. ... control catalytic activity one of the most fundamental ... reactions with mechanical force. This discovery paves the way ... influence of mechanical tension. The results of their research ...
Cached Biology Technology:Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 2Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 3Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft 4Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 2Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 3Ansell Healthcare Espresses Firm Commitment to Support Continued Education of Healthcare Professionals Worldwide 4A molecular ripcord for chemical reactions 2
(Date:11/3/2014)... Australia report that low birth weight and preterm birth ... replacements in adulthood. Findings published in the American College ... , indicate that low birth weight and pre-term babies ... to OA as adults. , According to the ... are diagnosed with clinical OA. Symptoms of OA range ...
(Date:11/2/2014)... November 2014)—In support of a bold quest to rid ... Gates Foundation today announced an award of US$156 million ... (MVI) in building new vaccines that will interrupt the ... "accelerating to zero" agenda. Such vaccines would ensure that ... called an "immunological bed net." , This approach ...
(Date:11/2/2014)... walk into a bar and bump into a biologist . ... to some late-night nerd sketch, researchers have taken this premise ... biology, namely, finding meaning in the rising oceans of genomic ... cancer mutations that genome-wide studies are publishing at a dizzying ... parse the signal from the noise (and there is no ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... of some insects or the deep black of a ... the nanostructure of a fly,s eyes, according to Penn ... and inexpensively copy biological surface structures. "Only a ... says Akhlesh Lakhtakia, the Charles Godfrey Binder (Endowed) Professor ...
... size guidelines for all-terrain vehicles (ATV) are inadequate to ... results from a study by researchers at the University ... found that national ATV size guidelines for youth ... frame or engine size do not assure a ...
... of sedentary and overweight older people placed on a four-month ... more fat, compared to older sedentary people who were placed ... study also showed that when older people diet without exercising, ... said senior researcher Bret H. Goodpaster. When they combined weight ...
Cached Biology News:Coating copies microscopic biological surfaces 2Coating copies microscopic biological surfaces 3Study finds ATV guidelines inadequate 2Older people who diet without exercising lose valuable muscle mass 2
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Functionally tested for consistent G-banding of chromosomes....
... Silver Staining Kit is uniquely formulated ... with minimal protein modification for optimal ... problems associated with traditional silver stains ... because the reagents used do not ...
...
Biology Products: